Review ArticleReview
Immuno-oncology combinations: raising the tail of the survival curve
Samuel J. Harris, Jessica Brown, Juanita Lopez and Timothy A. Yap
Cancer Biology & Medicine June 2016, 13 (2) 171-193; DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0015
Samuel J. Harris
1Drug Development Unit
Jessica Brown
1Drug Development Unit
Juanita Lopez
1Drug Development Unit
Timothy A. Yap
1Drug Development Unit
2Lung Unit, Royal Marsden Hospital and The Institute of Cancer Research, London SM2 5PT, UK
References
- 1.↵
- 2.↵
- Mellman I,
- Coukos G,
- Dranoff G.
- 3.↵
- Sharma P,
- Allison JP.
- 4.↵
- 5.↵
- Burnet FM.
- 6.↵
- Hanahan D,
- Weinberg RA.
- 7.↵
- Ibrahim AM,
- Wang Y,
- Lemoine NR.
- 8.↵
- Dunn GP,
- Old LJ,
- Schreiber RD.
- 9.↵
- 10.↵
- Schreiber RD,
- Old LJ,
- Smyth MJ.
- 11.↵
- 12.↵
- Matsushita H,
- Vesely MD,
- Koboldt DC,
- Rickert CG,
- Uppaluri R,
- Magrini VJ, et al.
- 13.↵
- Dupage M,
- Mazumdar C,
- Schmidt LM,
- Cheung AF,
- Jacks T.
- 14.↵
- Vesely MD,
- Kershaw MH,
- Schreiber RD,
- Smyth MJ.
- 15.↵
- Dunn GP,
- Koebel CM,
- Schreiber RD.
- 16.↵
- 17.↵
- 18.↵
- 19.↵
- 20.↵
- Monteiro J.
- 21.↵
- Walunas TL,
- Lenschow DJ,
- Bakker CY,
- Linsley PS,
- Freeman GJ,
- Green JM, et al.
- 22.↵
- 23.↵
- 24.↵
- Simpson TR,
- Li F,
- Montalvo-Ortiz W,
- Sepulveda MA,
- Bergerhoff K,
- Arce F, et al.
- 25.↵
- 26.↵
- 27.↵
- Robert C,
- Thomas L,
- Bondarenko I,
- O'Day S,
- Weber J,
- Garbe C, et al.
- 28.↵
- Ribas A,
- Kefford R,
- Marshall MA,
- Punt CJ,
- Haanen JB,
- Marmol M, et al.
- 29.↵
- 30.↵
- 31.↵
- 32.↵
- 33.↵
- 34.↵
- 35.↵
- 36.↵
- 37.↵
- 38.↵
- 39.↵
- 40.↵
- Zamarin D,
- Postow MA.
- 41.↵
- 42.↵
- van der Most RG,
- Currie AJ,
- Mahendran S,
- Prosser A,
- Darabi A,
- Robinson BWS, et al.
- 43.↵
- Zitvogel L,
- Galluzzi L,
- Smyth MJ,
- Kroemer G.
- 44.↵
- Hersh EM,
- O'day SJ,
- Powderly J,
- Khan KD,
- Pavlick AC,
- Cranmer LD, et al.
- 45.↵
- Lynch TJ,
- Bondarenko I,
- Luft A,
- Serwatowski P,
- Barlesi F,
- Chacko R, et al.
- 46.↵
- Reck M,
- Bondarenko I,
- Luft A,
- Serwatowski P,
- Barlesi F,
- Chacko R, et al.
- 47.↵
- Wolchok JD,
- Neyns B,
- Linette G,
- Negrier S,
- Lutzky J,
- Thomas L, et al.
- 48.↵
- Antonia SJ,
- Brahmer JR,
- Gettinger SN,
- Chow LQM,
- Juergens RA,
- Shepherd FA, et al.
- 49.↵
- Papadimitrakopoulou V,
- Patnaik A,
- Borghaei H,
- Stevenson J,
- Gandhi L,
- Gubens MA, et al.
- 50.↵
- Adams S,
- Diamond J,
- Hamilton E,
- Pohlmann P.
- 51.↵
- Mole RH.
- 52.↵
- Demaria S,
- Ng B,
- Devitt ML,
- Babb JS,
- Kawashima N,
- Liebes L, et al.
- 53.↵
- Reits EA,
- Hodge JW,
- Herberts CA,
- Groothuis TA,
- Chakraborty M,
- Wansley EK, et al.
- 54.↵
- Wu L,
- Wu MO,
- De La Maza L,
- Yun Z,
- Yu J,
- Zhao Y, et al.
- 55.↵
- Deng L,
- Liang H,
- Burnette B,
- Beckett M,
- Darga T,
- Weichselbaum RR, et al.
- 56.↵
- Dewan MZ,
- Galloway AE,
- Kawashima N,
- Dewyngaert JK,
- Babb JS,
- Formenti SC, et al.
- 57.↵
- Postow MA,
- Callahan MK,
- Barker CA,
- Yamada Y,
- Yuan J,
- Kitano S, et al.
- 58.↵Clinicaltrials.Gov search of radiotherapy pd-1, 2016. Available from: https://clinicaltrials.gov/ct2/results?term=radiotherapy+pd-1&Search=Search
- 59.↵
- 60.↵
- Duffy AG,
- Makarova-Rusher OV,
- Kerkar SP,
- Kleiner DE,
- Fioravanti S,
- Walker M, et al.
- 61.↵
- 62.↵
- Callahan MK,
- Masters G,
- Pratilas CA,
- Ariyan C,
- Katz J,
- Kitano S, et al.
- 63.↵
- Menard C,
- Blay JY,
- Borg C,
- Michiels S,
- Ghiringhelli F,
- Robert C, et al.
- 64.↵
- 65.↵
- Long GV,
- Stroyakovskiy D,
- Gogas H,
- Levchenko E,
- De Braud F,
- Larkin J, et al.
- 66.↵
- Ribas A,
- Butler M,
- Lutzky J,
- Lawrence DP,
- Robert C,
- Miller W, et al.
- 67.↵
- Ribas A,
- Hodi FS,
- Callahan M,
- Konto C,
- Wolchok J.
- 68.↵
- Rini BI,
- Stein M,
- Shannon P,
- Eddy SA,
- Stephenson J,
- Catlett L, et al.
- 69.↵
- Amin A,
- Plimack ER,
- Infante JR,
- Ernstoff MS,
- Rini BI,
- McDermott DF, et al.
- 70.↵
- 71.↵
- Ohm JE,
- Carbone DP.
- 72.↵
- 73.↵
- Hodi FS,
- Lawrence D,
- Lezcano C,
- Wu XQ,
- Zhou J,
- Sasada T, et al.
- 74.↵
- Rizvi NA,
- Antonia SJ,
- Shepherd FA,
- Chow LQ,
- Goldman J,
- Shen Y, et al.
- 75.↵
- Lieu C,
- Bendell J,
- Powderly JD,
- Pishvaian MJ,
- Hochster H,
- Eckhardt SG, et al.
- 76.↵
- Gardai SJ,
- Epp A,
- Law C-L.
- 77.↵Clinicaltrials.Gov search of brentuximab and nivolumab, 2016. Available from: https://clinicaltrials.gov/ct2/results?term=brentuximab+nivoluma b&Search=Search
- 78.↵
- Ozao-Choy J,
- Lee DJ,
- Faries MB.
- 79.↵
- Kantoff PW,
- Higano CS,
- Shore ND,
- Small EJ,
- Penson DF,
- Redfern CH, et al.
- 80.↵
- Drake CG,
- Quinn D,
- Dreicer R,
- Antonarakis E,
- Shore N,
- Corman J, et al.
- 81.↵
- 82.↵
- Le DT,
- Wang-Gillam A,
- Picozzi V,
- Greten TF,
- Crocenzi T,
- Springett G, et al.
- 83.↵
- Le DT,
- Lutz E,
- Uram JN,
- Sugar EA,
- Onners B,
- Solt S, et al.
- 84.↵
- van den Eertwegh AJM,
- Versluis J,
- van den Berg HP,
- Santegoets SJAM,
- van Moorselaar RJA,
- van der Sluis TM, et al.
- 85.↵Gvax pancreas vaccine (with cy) and crs-207 with or without nivolumab. Available from: https://clinicaltrials.gov/show/NCT02243371.
- 86.↵
- Andtbacka RH,
- Kaufman HL,
- Collichio F,
- Amatruda T,
- Senzer N,
- Chesney J, et al.
- 87.↵
- Long GV,
- Dummer R,
- Ribas A,
- Puzanov I,
- Michielin O,
- VanderWalde A, et al.
- 88.↵
- Puzanov I,
- Milhem MM,
- Andtbacka RHI,
- Minor DR,
- Hamid O,
- Li A, et al.
- 89.↵
- Horvat TZ,
- Adel NG,
- Dang TO,
- Momtaz P,
- Postow MA,
- Callahan MK, et al.
- 90.↵
- Patnaik A,
- Socinski MA,
- Gubens MA,
- Gandhi L,
- Stevenson J,
- Bachman RD, et al.
- 91.↵
- Atkins MB,
- Choueiri TK,
- Hodi FS,
- Thompson JA,
- Hwu W-J,
- McDermott DF, et al.
- 92.↵
- Antonia SJ,
- Goldberg SB,
- Balmanoukian AS,
- Sanborn RE,
- Steele K,
- Narwal R, et al.
- 93.↵
- Millward M,
- Underhill C,
- Lobb S,
- McBurnie J,
- Meech SJ,
- Gomez-Navarro J, et al.
- 94.↵
- Kudchadkar RR,
- Gibney GT,
- Weber J,
- Chen A,
- Smith K,
- Merek S.
- 95.↵
- Tarhini AA,
- Cherian J,
- Moschos SJ,
- Tawbi HA,
- Shuai YL,
- Gooding WE, et al.
- 96.↵
- 97.↵
- Matsuzaki J,
- Gnjatic S,
- Mhawech-Fauceglia P,
- Beck A,
- Miller A,
- Tsuji T, et al.
- 98.↵
- Sakuishi K,
- Apetoh L,
- Sullivan JM,
- Blazar BR,
- Kuchroo VK,
- Anderson AC.
- 99.↵
- 100.↵
- 101.↵
- Kwon BS,
- Hurtado JC,
- Lee ZH,
- Kwack KB,
- Seo SK,
- Choi BK, et al.
- 102.↵
- Ye QR,
- Song DG,
- Poussin M,
- Yamamoto T,
- Best A,
- Li CS, et al.
- 103.↵
- Kohrt HE,
- Colevas AD,
- Houot R,
- Weiskopf K,
- Goldstein MJ,
- Lund P, et al.
- 104.↵
- 105.↵
- Collins SM,
- Bakan CE,
- Swartzel GD,
- Efebera YA,
- Kwon HA,
- CiarlarieUo D, et al.
- 106.↵
- 107.↵
- Segal NH,
- Gopal AK,
- Bhatia S,
- Kohrt HE,
- Levy R,
- Pishvaian MJ, et al.
- 108.↵
- Gopal AK,
- Bartlett NL,
- Levy R,
- Houot R,
- Smith SD,
- Segal NH, et al.
- 109.↵
- Schaer DA,
- Hirschhorn-Cymerman D,
- Wolchok JD.
- 110.↵
- Guo Z,
- Wang X,
- Cheng D,
- Xia Z,
- Luan M,
- Zhang S.
- 111.↵
- Adler AJ,
- Vella AT.
- 112.↵Clinicaltrials.Gov search of Medi6469. Available from: https://clinicaltrials.gov/ct2/results?term=MEDI6469&Search =Search.
- 113.↵
- Bajor DL,
- Mick R,
- Riese MJ,
- Richman LP,
- Xu X,
- Torigian DA, et al.
- 114.↵
- Zippelius A,
- Schreiner J,
- Herzig P,
- Mueller P.
- 115.↵
- Cohen AD,
- Schaer DA,
- Liu C,
- Li Y,
- Hirschhorn-Cymmerman D,
- Kim SC, et al.
- 116.↵
- Infante JR,
- Burris HA,
- Ansell SM,
- Nemunaitis JJ,
- Weiss GR,
- Villalobos VM, et al.
- 117.↵
- 118.↵
- 119.↵
- 120.↵
- Nayak A,
- Hao Z,
- Sadek R,
- Dobbins R,
- Marshall L.
- 121.↵
- Gibney G,
- Hamid O,
- Lutzky J,
- Olszanski A,
- Gangadhar T,
- Gajewski T, et al.
- 122.↵
- Gangadhar TC,
- Hamid O,
- Smith DC,
- Bauer TM,
- Wasser JS,
- Luke JJ, et al.
- 123.↵
- Zakharia Y,
- Drabick J,
- Khleif S,
- Munn D,
- Link C,
- Vahanian N, et al.
- 124.↵
- Lin RL,
- Zhao LJ.
- 125.↵
- 126.↵
- Ries CH,
- Cannarile MA,
- Hoves S,
- Benz J,
- Wartha K,
- Runza V, et al.
- 127.↵
- Gil M,
- Komorowski MP,
- Seshadri M,
- Rokita H,
- Mcgray A,
- Opyrchal M, et al.
- 128.↵
- 129.↵Safety and efficacy study of ulocuplumab and nivolumab in subjects with solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT02472977.
- 130.↵
- 131.↵
- 132.↵Study of combination therapy with mogamulizumab (KW-0761) and nivolumab (ONO-4538/BMS-936558) in subjects with advanced solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT02476123?term=Study+of +combination+therapy+with+mogamulizumab+%28kw-0761%29+and+nivolumab+%28ono-4538%2Fbms-936558%29+in+subjects+with+advanced+solid+tumors&rank=1
- 133.↵Study of mogamulizumab + MEDI4736 and mogamulizumab + tremelimumab in subjects w/ advanced solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT02301130?term=Study+of +mogamulizumab+%2B+medi4736+and+mogamulizumab+%2 B+tremelimumab+in+subjects+w%2F+advanced+solid+tumors &rank=1
- 134.↵
- 135.↵Defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02546531?term=Defactinib +combined+with+pembrolizumab+and+gemcitabine+in+patient s+with+advanced+cancer&rank=1.
- 136.↵
- 137.↵
- Wolchok JD,
- Kluger H,
- Callahan MK,
- Postow MA,
- Rizvi NA,
- Lesokhin AM, et al.
- 138.↵
- Lopez J,
- Harris S,
- Roda D,
- Yap TA.
- 139.↵
- 140.↵
- Britten CM,
- Janetzki S,
- Van Der Burg SH,
- Huber C,
- Kalos M,
- Levitsky HI, et al.
- 141.↵
- 142.↵
- Topalian SL,
- Hodi FS,
- Brahmer JR,
- Smith DC,
- Mcdermott DF,
- Carvajal RD, et al.
- 143.↵
- Kefford R,
- Ribas A,
- Hamid O,
- Robert C,
- Daud A,
- Wolchok JD, et al.
- 144.↵
- 145.↵
- Rizvi NA,
- Mazières J,
- Planchard D,
- Stinchcombe TE,
- Dy GK,
- Antonia SJ, et al.
- 146.↵
- Omori S,
- Kenmotsu H,
- Abe M,
- Watanabe R,
- Sugino T,
- Wakuda K, et al.
- 147.↵
- Ock CY,
- Keam B,
- Kim S,
- Shin JY,
- Ahn YO,
- Kim TM, et al.
- 148.↵
- Berman DM,
- Wolchok J,
- Weber J,
- Hamid O,
- O'Day S,
- Chasalow SD.
- 149.↵
- Postow MA,
- Chasalow SD,
- Yuan J,
- Kuk D,
- Panageas KS,
- Cheng M, et al.
- 150.↵
- Weide B,
- Zelba H,
- Derhovanessian EA,
- Eigentler TK,
- Di Giacomo AM,
- Maio M, et al.
- 151.↵
- Yuan J,
- Adamow M,
- Ginsberg BA,
- Rasalan TS,
- Ritter E,
- Gallardo HF, et al.
- 152.↵
- Samaik AA,
- Yu B,
- Yu DH,
- Morelli D,
- Hall ML,
- Bogle D, et al.
- 153.↵
- Snyder A,
- Makarov V,
- Merghoub T,
- Yuan J,
- Zaretsky JM,
- Desrichard A, et al.
- 154.↵
- Rizvi NA,
- Hellmann MD,
- Snyder A,
- Kvistborg P,
- Makarov V,
- Havel JJ, et al.
- 155.↵
- Bulliard Y,
- Jolicoeur R,
- Zhang JM,
- Dranoff G,
- Wilson NS,
- Brogdon JL.
- 156.↵
- 157.↵
- Tumeh PC,
- Harview CL,
- Yearley JH,
- Shintaku IP,
- Taylor EJ,
- Robert L, et al.
- 158.↵
- Rashidian M,
- Keliher EJ,
- Bilate AM,
- Duarte JN,
- Wojtkiewicz GR,
- Jacobsen JT, et al.
- 159.↵
- 160.↵
- Robert C,
- Ribas A,
- Wolchok JD,
- Hodi FS,
- Hamid O,
- Kefford R, et al.
- 161.↵
- 162.↵
- Weber JS,
- Dummer R,
- De Pril V,
- Lebbe C,
- Hodi FS,
- Mdx010-20 I.
- 163.↵
- Attia P,
- Phan GQ,
- Maker AV,
- Robinson MR,
- Quezado MA,
- Sherry RM, et al.
- 164.↵
- Finke LH,
- Wentworth K,
- Blumenstein B,
- Rudolph NS,
- Levitsky H,
- Hoos A.
- 165.↵
- 166.↵
- Wolchok JD,
- Hoos A,
- O'Day S,
- Weber JS,
- Hamid O,
- Lebbé C, et al.
- 167.↵
- Nishino M,
- Giobbie-Hurder A,
- Gargano M,
- Suda M,
- Ramaiya NH,
- Hodi FS.
- 168.↵
- Nishino M,
- Gargano M,
- Suda M,
- Ramaiya NH,
- Hodi FS.
In this issue
Immuno-oncology combinations: raising the tail of the survival curve
Samuel J. Harris, Jessica Brown, Juanita Lopez, Timothy A. Yap
Cancer Biology & Medicine Jun 2016, 13 (2) 171-193; DOI: 10.20892/j.issn.2095-3941.2016.0015
Jump to section
- Article
- Abstract
- Introduction
- Immune surveillance, editing and suppression
- Current immunotherapeutic strategies
- Combinations with chemotherapy
- Combinations with radiotherapy
- Combinations with molecularly targeted agents
- Combinations with vaccine therapies
- Combinations with immunotherapies
- Combinations with other checkpoint inhibitors
- Combinations with immune pathway agonists
- Targeting the tumor microenvironment
- Trial designs for immunotherapy combination strategies
- Incorporating biomarker studies into immuno-oncology trials
- Monitoring of toxicities in early phase clinical trials
- Assessing antitumor responses in immunotherapy combination trials
- Conclusions
- Footnotes
- References
- Figures & Data
- Info & Metrics
- References
Related Articles
- No related articles found.
Cited By...
- Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
- Immuno-oncology trends: preclinical models, biomarkers, and clinical development
- Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors